CRITICAL PATH INSTITUTE, LIMITED

Their core work

Critical Path Institute is a non-profit drug-development catalyst, here operating through its Ireland-registered European entity. Their contribution is not wet-lab research but the connective tissue of modern drug development: shared data standards, innovative clinical trial designs, and consensus methodology that helps regulators, pharma and academia evaluate new medicines faster. In H2020 they focus this capability on tuberculosis, working inside large European consortia that move candidate TB regimens from preclinical pharmacology through to AI-supported adaptive clinical trials. For partners, their real value is translating scientific progress into a form that regulators and sponsors can actually use.

What they specialise in

How they've shifted over time

In 2020 they entered H2020 through ERA4TB with a preclinical, microbiology-heavy focus on accelerating a pan-TB drug regimen. By 2021, with UNITE4TB, their footprint shifted downstream into clinical development — innovative trial platforms, adaptive trial design, and AI applied to new chemical entities. The trajectory is a clean walk along the TB drug pipeline: from bench regimen assembly toward patient trials and data-driven evaluation.

They are moving from preclinical TB regimen work into AI-enabled clinical trial platforms — a sensible partner for anyone building data-driven, adaptive clinical development programmes in infectious disease.

How they like to work

They join as a participant in very large health consortia — 63 unique partners across just 2 projects signals mega-consortium work typical of IMI-style public-private partnerships. They have never coordinated in H2020, instead bringing a specialist regulatory-science contribution to industry-led TB alliances. Expect them to act as a neutral methodology and data-standards partner rather than a task leader on bench science.

63 unique consortium partners across 14 countries in just two projects — a highly connected hub position inside European TB drug-development networks, reflecting mega-consortium participation rather than a narrow bilateral pattern.

What sets them apart

They are an Ireland-registered SME arm of a well-known non-profit that specialises in bringing regulators, pharma, and academia to a common table around drug-development methodology. Inside H2020 they are one of very few partners focused specifically on tuberculosis regimen acceleration combined with trial-platform and AI methodology — not bench chemistry, not a CRO, but a neutral methodology and data-standards contributor. Partner with them when a consortium needs credibility with regulators and structured clinical development expertise, not wet-lab capacity.

Highlights from their portfolio

• UNITE4TB
  Their largest H2020 engagement (EUR 2.39M) and the more advanced work — an academia-industry clinical trial platform combining adaptive trial design with AI for new TB drug regimens.
• ERA4TB
  Flagship European accelerator for a pan-TB drug regimen, anchoring their preclinical pharmacology and microbiology contribution (EUR 1.70M).